Introduction
There have been reports of osseous metaplasia, or bone formation, in diverse malignancies, including the colon, the lung, the gastrointestinal tract, the thyroid, the breast and the pancreas from as early as 1923.
1,2 Though a rare occurrence, tumors that naturally calcify decelerate in growth rate. 3 This observation led to an entire line of research that has resulted in isolation and understanding of a number of protein factors that govern bone formation. 1, 4 One of the most interesting of these proteins is bone morphogenetic protein 2 (BMP-2), a cytokine factor sequenced in 1993. 5 BMP-2 is one of the 30 identified bone morphogenetic proteins, 4 and has been found to regulate the differentiation of uncommitted cells along osteoblastic pathways. 6 It is a 115-amino acid protein that was identified for its ability to recruit mesenchymal stem cells and promote the differentiation of these stem cells to form bone. 5 In addition to the osteoinductive properties of BMP-2, in recent years this protein has been found to exact inhibitory effects on the growth of certain tumors. [7] [8] [9] We predicted that we could deliver this protein to tumor cells as a strategy for specifically retarding tumor cell growth and inducing heterotopic ossification.
Various virus-based vectors have been engineered to efficiently transduce cancer cells to introduce genes designed to promote the elimination of those cells. One particularly promising family of virus-based vectors used in cancer therapy is derived from the herpes simplex virus (HSV) type-1. 10, 11 This virus, which in its wild-type form produces cold sores, has been genetically engineered to be even safer and to efficiently transduce a broad spectrum of human cancers. 10, 11 In this study, we employ replication-incompetent HSV amplicon vectors. These vectors harbor no viral genes, only the non-protein encoding packaging sequence (pac) and HSV origin of replication to facilitate the propagation of viral particles. As these viral particles are devoid of all viral protein-encoding sequences, they can harbor up to 130 kb of genetic material and do not replicate or cause HSV-related disease, hence making them inherently useful and very safe. We inserted the human BMP-2 gene downstream of the promoter for human carcinoembryonic antigen (CEA), a protein normally only produced in the adult by cancer cells, into a parental HSV amplicon vector. 12 We hypothesized that placing BMP-2 under the control of the CEA promoter would restrict BMP-2 expression to cancer cells that can express CEA. We sought to determine if this viral vector may be useful as a cancer treatment agent by retarding tumor cell growth and/or eliciting bone formation.
Materials and methods

Construction of HSV amplicon vector HSV-CEA-BMP2
The parental pHSVminiOris vector, containing the HSV packaging sequence (pac) and origin of replication (Figure 1 ), was used. 13 This vector also has a multiple cloning site to facilitate insertion of promoter elements, therapeutic transgenes and 3 0 regulatory sequences. A plasmid containing the intact BMP-2 gene was a kind gift from Dr Babak Mehrara (Memorial Sloan-Kettering Cancer Center, New York, NY). The 1.6-kb BMP-2 coding sequence was isolated by digestion with restriction enzymes XbaI and SpeI. This BMP-2 sequence was then ligated into the multiple cloning site between the XbaI and SpeI sites (Quick Ligase, NEB, Beverly, MA).
The human CEA genomic sequence was obtained as a bacterial plasmid from Invitrogen (San Diego, CA). The 1869-bp CEA enhancer-promoter (CEA-EP) sequence was amplified by polymerase chain reaction using forward (5 0 -TATGATTAACGCGTCCTGCAGGGCCCACTAGA GC-3 0 ) and reverse (5 0 -TGGCTGTAAGCTTCCCATGG TCTCTGCTGTCTGC-3 0 ) primers. The resultant CEA-EP sequence was then ligated into the HindIII site in the multiple cloning site of the pHSVminiOris to produce HSV-CEA-BMP2. The sequence was confirmed by polymerase chain reaction and restriction digests. The restriction digests are shown in Figure 1b .
Helper virus-free amplicon vector packaging Amplicon vectors were packaged as previously described.
14 Viral pellets were re-suspended in 100-ml phosphate-buffered saline and stored at À80 1C until use. Vectors will be titered as described previously. 15 A control amplicon expressing the lacZ reporter gene, HSVlac, was described previously 16 and packaged in an identical manner.
Cell lines CEA-expressing cell lines: The cell lines used were LS174T, a human colon cancer cell line, and MCF7, a human breast cancer cell line. These cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). LS174T and MCF7 were both cultured in minimum essential medium containing nonessential amino acids, 10% fetal calf serum, 1-mM sodium pyruvate at 1.5-g l À1 sodium bicarbonate. The cell lines were maintained in a 5% CO 2 humidified incubator at 37 1C, and sub-cultured twice weekly. After plating and transfection procedures, cells were routinely incubated for 12 h before viral infection to allow for adherence to cell culture plates.
CEA-negative cell lines: The CEA-negative cell lines used were LS141, a human dedifferentiated liposarcoma cell line and T47D, a human breast cancer cell line. LS141 cells were a kind gift from Dr Samuel Singer (Memorial Sloan-Kettering Cancer Center, New York, NY). T47D Bone formation and cancer S Fong et al cells were obtained from the American Type Culture Collection (Manassas, VA). LS141 was maintained in Dulbecco's modified Eagle's medium F-12 supplemented with 4.5-g l À1 glucose and 10% fetal calf serum. T47D was maintained in roswell park memorial institute 1640 media containing 10-mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 10% fetal calf serum, 1-mM of sodium pyruvate, at 1.5-g l À1 sodium bicarbonate at 4.5-g l
À1
glucose.
Mesenchymal stem cells: The SF2 mesenchymal stem cell line was a kind gift from Dr Lorenz Studer (Memorial Sloan-Kettering Cancer Center, New York, NY). It was maintained in a 5% CO 2 humidified incubator at 37 1C, and sub-cultured twice a week. Cells were grown in aminimum essential medium supplemented with 10% fetal calf serum, 100-U ml À1 penicillin and 100-mg ml À1 streptomycin. All culture surfaces were coated with 0.5% gelatin.
Verification of CEA expression LS174T, MCF7, LS141 and T47D cells were plated at 1 Â 10 5 cells per well in a 12-well flat-bottom plates (BD Falcon, Franklin Lakes, NJ). A phycoerythrin-labeled antibody specific for human CEA, anti-human CD66 (BD Biosciences Pharmingen, Franklin Lakes, NJ), was applied at a volume of 5 ml per well and incubated at room temperature for 1 h. Red fluorescence was detected using a Zeiss LSM 510 confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany) enhanced by MetaMorph Imaging System (Downingtown, PA). Pictures were taken with Retiga EX digital CCD camera (Qimaging, Surrey, BC, Canada).
Evaluation of BMP-2 production
To assess BMP-2 expression from HSV-CEA-BMP2 in cell lysates and supernatants, LS174T, MCF7, T47D and LS141 were plated in 12-well flat bottom plates (BD Falcon). LS174T were plated at 1 Â 10 6 cells per well, MCF7 were plated at 1 Â 10 5 , T47D were plated at 1 Â 10 5 and LS141 were plated at 5 Â 10 4 . The cells were plated to achieve 80% confluency to optimize for HSV amplicon transduction. After a 24-h incubation period, cells were exposed to HSV-CEA-BMP2 at a multiplicity of infection (MOI) of 0.5. At daily intervals, cell lysates and supernatants were collected. The samples were used to quantify the levels of BMP-2 using an enzyme-linked immunosorbent assay (R&D systems, Minneapolis, MN). To quantify, the plates were read on a Spectra Max 190 (Molecular Devices Corporation, Union City, CA) using Softmax Pro software (Molecular Devices Corporation, Union City, CA) at absorbances of 450 and 570 nm.
Effect of HSV-CEA-BMP2 on tumor growth Carcinoembryonic antigen-positive (MCF7 and LS174T) and CEA-negative (T47D and LS141) cells were plated at 2 Â 10 4 cells per well in a 24-well flat-bottom culture plate (BD Falcon). After a 12-h incubation, cells were exposed to HSV-CEA-BMP2 at an MOI of 0.5. At daily intervals, cancer cell survival was determined by cell counting. All samples were tested in triplicate and repeated.
Effect of BMP-2 expression on mesenchymal stem cell differentiation LS174T cells were plated in a 750-cm 3 flask, which holds approximately 10 7 cells per flask (BD Falcon). Once the cells were at least 80% confluent, they were exposed to HSV-CEA-BMP2 at an MOI of 0.5. After 72 h, when BMP-2 expression is greatest, the supernatant and cells were collected by scraping. The mixture was then sonicated after adding protease inhibitors cocktail (BD Biosciences) and phenylmethylsulfonyl fluoride. The cell lysates or collected supernatants were then applied to SF2 mesenchymal stem cells. For negative controls, stem cell plates were left untreated and other plates were treated with supernatants or lysates of uninfected LS174T. After 7 and 14 days, the various stem cell plates were collected and assayed for alkaline phosphatase using histochemical staining with 85L2-1KT (Sigma-Aldrich, St Louis, MO). 17 
Statistical analysis
Data are expressed as the mean±s.d. Comparisons between groups were performed with a two-tailed Student's t-test.
Results
HSV-CEA-BMP2 transduction results in the expression of BMP-2 specifically in CEA-positive cells
To test the specificity of the amplicon, two known CEApositive cell lines, LS174T and MCF7, and two known CEA-negative cell lines, LS141 and T47D, were used. The CEA status of the cell lines were confirmed by staining with an antibody specific for human CEA. The obvious red fluorescence achieved with this phycoerythrin-labeled antibody is shown for LS174T cells in Figure 1c .
All cells were also exposed to control HSVlac vector carrying the marker gene lacZ and were processed for X-gal histochemistry, which stains cells blue if cells are effectively transduced. All cells, whether CEA-positive or negative, stained blue starting on day 1 after infection (not shown). This was sustained through the seven days assayed. This confirmed that the lack of BMP-2 expression in CEA-negative cell lines was not because of an issue with viral infection, but specificity of the CEA-promoter and its effect on gene expression.
The cell lines were subsequently transduced with the HSV-CEA-BMP2 amplicon at MOI 0.5 and then assayed for BMP-2 using an enzyme-linked immunosorbent assay. BMP-2 expression was found only in CEA-positive cell lines. No BMP-2 production was observed at any time point after exposure to the viral vector in the CEAnegative cell lines (data not shown) or after exposure of the cell lines to the control amplicon (HSVlac) (data not shown).
In the CEA-positive cell lines transduced with HSV-CEA-BMP2, significant production of BMP-2 occurred after day 1 and was sustained through day 7. BMP-2 production peaked on day 3 and reached levels as high as 275 pg ml À1 in LS174T cells and 300 pg ml À1 in MCF7 cells (Figure 2 ).
HSV-CEA-BMP2 retards tumor growth
To determine whether sufficient BMP-2 levels are expressed after amplicon transduction to mediate a growth-inhibitory activity, two breast cancer cell lines, one CEA positive (MCF7) and one CEA negative (T47D), were transduced with HSV-CEA-BMP2. The cells were trypsinized and counted daily for seven days after vector incubation. Both cell lines are known to be inhibited in the presence of BMP-2. 9 Results of a representative experiment are shown in Figure 3 . The growth of the CEA-expressing cell line MCF7 was retarded significantly by the production of BMP-2 (Figure 3a) , whereas growth of the CEA-negative T47D cell line was not inhibited (Figure 3b ). There was an 88% suppression of growth by HSV-CEA-BMP2 at MOI 0.1; and a 96% suppression of growth at MOI of 0.5.
As a control, cells were infected with the viral vector HSVlac to determine whether the decrease in proliferation was due to BMP-2 production or to exposure to the viral vector. HSVlac produced a minimal decrease in cell growth (30%), but clearly not to the extent that HSV-CEA-BMP2 did (Po0.001), indicating that the inhibition of growth by the latter was primarily due to BMP-2 production (data not shown).
Effect of BMP-2 expression on mesenchymal stem cell differentiation Alkaline phosphatase expression is a marker indicating the differentiation of stem cells to bone lineage. SF2 mesenchymal stem cells express low levels (o5%) of alkaline phosphatase at baseline. After exposure to lysates of untreated LS174T cells, no change of alkaline phosphatase expression was found. After exposure to lysates of LS174T cells that had been treated with HSV-CEA-BMP2 there was a significant increase in the percentage of alkaline phosphatase-expressing cells (Po0.001) (Figure 4 ). Over 30% of the cells were stained positive by day 7, indicating differentiation to bone. Similarly, increased alkaline phosphatase expression was found after the exposure of SF2 stem cells to supernatants from HSV-CEA-BMP2 infected MCF7 cells, but not after exposure to supernatants from uninfected MCF7 cells (data not shown).
Discussion
Tumor calcification or ossification occurs only rarely, but is associated with the transformation of tumors to a slowgrowing phenotype. The interesting interaction of tumor Figure 2 Bone morphogenetic protein 2 (BMP-2) production in cells exposed to pHSV-CEA-BMP2. LS174T, MCF7, T47D and LS141 were exposed to HSV-CEA-BMP2 and levels of BMP-2 were assayed by enzyme-linked immunosorbent assay (ELISA). Carcinoembryonic antigen (CEA)-negative cell lines, LS141 and T47D, did not produce BMP-2 over the five days assayed (not shown). After exposure to pHSV-CEA-BMP2, significant amounts of BMP-2 were detected for the two known CEA-positive cell lines, LS174T and MCF7, over the five days assayed. Infection of cell lines with the control amplicon herpes simplex virus (HSV)-lacZ did not produce detectable BMP-2 (not shown). and bone started Huggins 18 down a path of discovery involving the mechanisms of bone growth. Reddi et al. [19] [20] [21] developed a field that has elucidated many of the basic mechanisms of bone growth and repair, which has led to the isolation of a number of growth and inhibitory factors that are essential to the regulatory processes of bone differentiation.
20,21 BMP-2 is one of the key regulatory factors that not only attracts circulating mesenchymal cells to sites of bone injury, but also elicits the differentiation of these cells. This protein has also been found to retard the growth of certain tumor cells. 2 We postulated that viral vectors designed to efficiently express BMP-2 in tumors could potentially have therapeutic effects. Further, we sought to determine if the mechanism of this effect might be a direct retardation of growth or even bone formation. This study is a proof-of-principal study designed to examine these issues. The results indicate that the local expression of BMP-2 did indeed produce both retardation of tumor and encourage mesenchymal stem cell differentiation into bone lineage. Thus, this novel viral vector can produce both a 'Hypnos' and a 'Medusa' effect; it halts tumor growth and causes ossification.
Viral vectors have been widely studied for cancer gene therapy in attempts to produce changes in local tumor environment. 10, 11, 22 HSV vectors are particularly attractive. They are safe and 490% of humans have antibodies directed against HSV, indicating wide exposure, but few have clinical sequelae. Even in patients who have clinical HSV infection, the majority manifest as simple cold sores. 23 This is also a vector system that has been shown to be effective in gene transfer even when the host has preestablished circulating anti-HSV antibodies. 24, 25 The subclass of HSV vectors used in these studies, amplicon vectors, is particularly safe. This is a replication-incompetent vector system that uses a helper virus-free approach for production. 22 The current data indicate that HSV amplicon vectors can be used to rapidly and efficiently infect tumor cells to achieve local target molecule production.
The CEA gene promoter was chosen to further increase tumor specificity of BMP-2 expression. CEA is not normally expressed in adult humans, 26, 27 but is expressed by a wide range of cancers, thus allowing a single vector to potentially target therapeutic transgene expression specifically within diverse cancers. CEA is expressed in colon, rectal, gallbladder, breast, lung, esophageal and pancreatic cancers. 28 Circulating levels of CEA are typically used to assess patients for the presence and the amount of cancer. 28 This is also the reason that many previous therapeutic strategies have attempted to exploit the expression of this protein in cancer cells. 29 HSV-CEA-BMP2 is designed not only to exploit the safety of HSV vectors, but also the specificity of targeting to CEAexpressing tumors. These studies indicate that this vector produces the desired biological effects in vitro. Actual toxicity-to-efficacy ratio evaluation must be determined in in vivo models and eventually in human clinical trials. A logical next step to further these experiments will be to incorporate a packaging sequence into the amplicon to allow for the secretion of BMP-2, and to test the efficacy of the amplicon in growth inhibition and calcification of CEA-expressing tumors in an in vivo model. This study describes the construction and production of a new viral vector which produces BMP-2 in cancer cells that naturally produce CEA. The goal was to mimic a natural phenomenon, calcification of tumors, which is rare in nature but leads to slowing of cancer growth. The results indicate that HSV-CEA-BMP2 has the potential to generalize this beneficial effect to all CEA-expressing tumors.
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